LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Corinne Faivre‐Finn, David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste, David R. Spigel, Marina Chiara Garassino, Martin Reck, Suresh Senan, Jarushka Naidoo, Andreas Rimner, Yi‐Long Wu, Jhanelle E. Gray, Mustafa Özgüroğlu, K.H. Lee, Michael Newton, L. Wang, Piruntha Thiyagarajah, Scott Antonia